A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Miroslaw Mazurczak MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Active - Open to Accrual
For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.
Back to Clinical Trials list